





RealRate

# HEALTH SERVICES 2019

## Viridian Therapeutics Inc.\DE Rank 34 of 73



The relative strengths and weaknesses of Viridian Therapeutics Inc.\DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc.\DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 304% points. The greatest weakness of Viridian Therapeutics Inc.\DE is the variable Research And Development Expense, reducing the Economic Capital Ratio by 92% points.

The company's Economic Capital Ratio, given in the ranking table, is 107%, being 74% points above the market average of 32%.

Input Variable	Value in 1000 USD
Assets, Current	65,370
Assets, Non-Current	50
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	11,049
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	6,733
Long Term Liabilities	8,070
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	-3.0
Other Expenses	873
Other Liabilities	0
Other Net Income	1,254
Other Revenues	8,386
Property Plant and Equipment	727
Research And Development Expense	30,421
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	66,147
Liabilities	14,803
Expenses	42,343
Revenues	8,386
Stockholders Equity	51,344
Net Income	-32,703
Comprehensive Net Income	-32,706
Economic Capital Ratio	107%